Tiragolumab/Atezolizumab Does Not Meet OS End Point in Metastatic NSCLC
Tiragolumab with atezolizumab, when compared with placebo with atezolizumab, failed to reach its overall survival end point in patients with NSCLC.
Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
Capivasertib Combo Significantly Improves rPFS in PTEN-Deficient HSPC
Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.
Collaboration Fosters Treatment Advancements for Young Lymphoma Populations
A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.
SPM AE Incidence After CAR T-Cell Therapy in Lymphoma and Myeloma
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.
